肝脏外科医生眼中的2021 ASCO

[1] Adjuvant nivolumab for hepatocellular carcinoma (HCC) after surgical resection (SR) or radiofrequency ablation (RFA) (NIVOLVE):Aphase 2 prospective multicenter single-arm trial and exploratory biomarker analysis .2 Kudo M,Ueshima K,Nakahira S,et al. J Clin Oncol . 2021

[2] A real-world study of PD-1 inhibitors combined with TKIs for HCC with major vascular invasion as the conversion therapy:A prospective non-randomized,open-label cohort study .2 Zhang W,Hu B,Han J,et al. Ann Oncol .

[3] Preliminary results of the phase II ALTER-H004:Anlotinib combined with TACE as adjuvant therapy in hepatocellular carcinoma patients at high risk of post surgery recurrence .2 Wu Z,Wang Z,Zhang L,et al. J Clin Oncol . 2021

[4] Final results of a randomized,open label,perioperative phase IIstudy evaluating nivolumab alone or nivolumab plus ipilimumab in patients with resectable HCC .2 Kaseb AO,Cao HST,Mohamed YI,et al. J Clin Oncol . 2021

[5] Combination therapy for advanced hepatocellular carcinoma: do we see the light at the end of the tunnel?[J] . Zhang Ti,Merle Philippe,Wang Huaqi,Zhao Haitao,Kudo Masatoshi. epatobiliary surgery and nutrition . 2021 (2)

[6] Preliminary efficacy and safety of perioperative treatment of camrelizumab combined with apatinib in resectable hepatocellular carcinoma (HCC):A prospective phaseⅡstudy .2 Xia YX,Wang P,Pu LY,et al. J Clin Oncol . 2021

[7] Neoadjuvant transarterial infusion chemotherapy with FOLFOX could improve outcomes of resectable BCLC stage A/B hepatocellular carcinoma patients beyond Milan criteria:An interim analysis of a multi-center,phase 3,randomized,controlled clinical trial .2 Li SH,Zhong C,Li Q,et al. J Clin Oncol . 2021

[8] Salvage surgery following downstaging of unresectable hepatocellular carcinoma - A strategy to increase resectability [J]. ANNALS OF SURGICAL ONCOLOGY, 2007, 14 (12) : 3301 - 3309

[9] Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial[J] . Jordi Bruix,Tadatoshi Takayama,Vincenzo Mazzaferro,Gar-Yang Chau,Jiamei Yang,Masatoshi Kudo,Jianqiang Cai,Ronnie T Poon,Kwang-Hyub Han,Won Young Tak,Han Chu Lee,Tianqiang Song,Sasan Roayaie,Luigi Bolondi,Kwan Sik Lee,Masatoshi Makuuchi,Fabricio Souza,Marie-Aude Le Berre,Gerold Meinhardt,Josep M Llovet. he Lancet Oncology . 2015 (13)

[10] Transplantation versus hepatectomy for HCC beyond the Milan criteria: A propensity score analysis[J] . Jun-yi shen,Chuan Li,Tian-fu Wen,Lv-nan Yan,Bo Li,Wen-tao Wang,Jia-yin Yang,Ming-qing Xu,Jun wen. nternational Journal of Surgery . 2017

[1] Adjuvant nivolumab for hepatocellular carcinoma (HCC) after surgical resection (SR) or radiofrequency ablation (RFA) (NIVOLVE):Aphase 2 prospective multicenter single-arm trial and exploratory biomarker analysis .2 Kudo M,Ueshima K,Nakahira S,et al. J Clin Oncol . 2021

[2] A real-world study of PD-1 inhibitors combined with TKIs for HCC with major vascular invasion as the conversion therapy:A prospective non-randomized,open-label cohort study .2 Zhang W,Hu B,Han J,et al. Ann Oncol .

[3] Preliminary results of the phase II ALTER-H004:Anlotinib combined with TACE as adjuvant therapy in hepatocellular carcinoma patients at high risk of post surgery recurrence .2 Wu Z,Wang Z,Zhang L,et al. J Clin Oncol . 2021

[4] Final results of a randomized,open label,perioperative phase IIstudy evaluating nivolumab alone or nivolumab plus ipilimumab in patients with resectable HCC .2 Kaseb AO,Cao HST,Mohamed YI,et al. J Clin Oncol . 2021

[5] Combination therapy for advanced hepatocellular carcinoma: do we see the light at the end of the tunnel?[J] . Zhang Ti,Merle Philippe,Wang Huaqi,Zhao Haitao,Kudo Masatoshi. epatobiliary surgery and nutrition . 2021 (2)

[6] Preliminary efficacy and safety of perioperative treatment of camrelizumab combined with apatinib in resectable hepatocellular carcinoma (HCC):A prospective phaseⅡstudy .2 Xia YX,Wang P,Pu LY,et al. J Clin Oncol . 2021

[7] Neoadjuvant transarterial infusion chemotherapy with FOLFOX could improve outcomes of resectable BCLC stage A/B hepatocellular carcinoma patients beyond Milan criteria:An interim analysis of a multi-center,phase 3,randomized,controlled clinical trial .2 Li SH,Zhong C,Li Q,et al. J Clin Oncol . 2021

[8] Salvage surgery following downstaging of unresectable hepatocellular carcinoma - A strategy to increase resectability [J]. ANNALS OF SURGICAL ONCOLOGY, 2007, 14 (12) : 3301 - 3309

[9] Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial[J] . Jordi Bruix,Tadatoshi Takayama,Vincenzo Mazzaferro,Gar-Yang Chau,Jiamei Yang,Masatoshi Kudo,Jianqiang Cai,Ronnie T Poon,Kwang-Hyub Han,Won Young Tak,Han Chu Lee,Tianqiang Song,Sasan Roayaie,Luigi Bolondi,Kwan Sik Lee,Masatoshi Makuuchi,Fabricio Souza,Marie-Aude Le Berre,Gerold Meinhardt,Josep M Llovet. he Lancet Oncology . 2015 (13)

[10] Transplantation versus hepatectomy for HCC beyond the Milan criteria: A propensity score analysis[J] . Jun-yi shen,Chuan Li,Tian-fu Wen,Lv-nan Yan,Bo Li,Wen-tao Wang,Jia-yin Yang,Ming-qing Xu,Jun wen. nternational Journal of Surgery . 2017